In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28. PTI/File
Tribune Web Desk
Chandigarh, May 13
National regulator Drugs Controller General of India (DCGI) has accepted the recommendation of the Subject Expert Committee (SEC) and accorded permission to conduct the phase-II/III clinical trials of Covaxin in the age group 2 to 18 years.
Also read: Covaxin recommended for trial on 2-18 age group
Covaxin manufacturer Bharat Biotech had proposed to carry out the trial, which will be conducted on 525 healthy volunteers.
In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.
As rapid regulatory response, the proposal was deliberated by the SEC on May 11.
Join Whatsapp Channel of The Tribune for latest updates.
Most Read In 24 Hours
Don't Miss
View All
Top News
Israel attacks Iran's air base, sources say, drones reported over Isfahan
Iran fires air defence batteries at Isfahan air base and nuc...
2 Indian-origin men among 6 arrested in Canada's biggest-ever heist; Here is how $22.5 million were robbed from Toronto's main airport
Parmpal Sidhu, 54, and Amit Jalota, 40, both from Ontario, w...
Central Consumer Protection Authority asks FSSAI to probe claim of Nestle adding sugar to baby products
The National Commission for Protection of Child Rights (NCPC...
Lok Sabha elections 2024: Voting under way in 102 seats, leaders urge people to turn up in large numbers
Polling for assembly elections in the north-eastern states o...
